• Mie Torii, Motomu Hashimoto, Akiko Hanai, Takao Fujii, Moritoshi Furu, Hiromu Ito, Ryuji Uozumi, Masahide Hamaguchi, Chikashi Terao, Wataru Yamamoto, Miyabi Uda, Kazuko Nin, Satoshi Morita, Hidenori Arai, and Tsuneyo Mimori.
• a Department of Human Health Sciences, Graduate School of Medicine , Kyoto University , Kyoto , Japan.
• Mod Rheumatol. 2019 Jul 1; 29 (4): 589-595.

AbstractObjectives: Sarcopenia is characterized by loss of muscle strength and mass, leading to falls and adverse health outcomes. Our aim was to determine the prevalence of sarcopenia in patients with rheumatoid arthritis (RA) and to identify factors associated with sarcopenia in these patients. Methods: A cross-sectional study of 388 consecutive women with RA was conducted, assessing muscle mass and strength, and walking speed. Falls and bone fractures sustained over the prior year were evaluated. The association between sarcopenia and RA characteristics, falls, and bone fractures was evaluated using logistic regression analyses. Results: The prevalence of sarcopenia was 37.1% (14.7%, severe sarcopenia; 22.4%, sarcopenia), with 49.0% classified as having low muscle mass. The incidence of falls, fractures, and lower bone mineral density was higher in patients with than without sarcopenia. Age, RA duration, Steinbrocker's stage, the high Mini-Nutritional Assessment-Short Form score and the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) were independent factors associated with sarcopenia. Conclusion: We confirmed that sarcopenia develops in a significant proportion of patients with RA. Age, longer disease duration, joint destruction and malnutrition were positively associated with sarcopenia, with the use of bDMARDs being negatively associated.

19 keywords...

hide…